Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Work In Process (2022 - 2025)

Historic Work In Process for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to $569262.0.

  • InMed Pharmaceuticals' Work In Process rose 12237.49% to $569262.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $569262.0, marking a year-over-year increase of 12237.49%. This contributed to the annual value of $26695.0 for FY2025, which is 1337.57% down from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Work In Process stood at $569262.0, which was up 12237.49% from $422798.0 recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Work In Process high stood at $1.7 million for Q2 2022, and its period low was $18446.0 during Q3 2024.
  • Moreover, its 4-year median value for Work In Process was $373256.0 (2025), whereas its average is $424701.1.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Work In Process plummeted by 9400.58% in 2024, and later skyrocketed by 219208.5% in 2025.
  • InMed Pharmaceuticals' Work In Process (Quarter) stood at $798813.0 in 2022, then plummeted by 76.59% to $186980.0 in 2023, then surged by 36.91% to $255992.0 in 2024, then skyrocketed by 122.37% to $569262.0 in 2025.
  • Its last three reported values are $569262.0 in Q4 2025, $422798.0 for Q3 2025, and $26695.0 during Q2 2025.